Fortrea Acquires Worldwide Clinical Trials' Early Phase Division for $45M, Adds 200-Bed CPU and GLP Lab
- Fortrea acquires three Texas facilities from Worldwide Clinical Trials: a 200-bed GCP-compliant clinical pharmacology unit in San Antonio, a 60,000 sq ft GLP bioanalytical lab in Austin, and a biospecimen storage facility in Pflugerville.
- Integration eliminates operational handoff between PK sample collection and bioanalytical processing, reducing delays and logistical complexity in early-phase studies.
- Worldwide retains global healthy volunteer site network under strategic alliance with Fortrea and redirects capital to late-stage oncology, neuroscience, and rare disease businesses.
Operational Impact
Fortrea's acquisition of Worldwide's 200-bed San Antonio CPU and Austin GLP lab creates an integrated early-phase platform that eliminates coordination delays between clinical and bioanalytical functions, strengthening its end-to-end Phase I–IV development offering.
Source: PharmaSource RSS